🚀 VC round data is live in beta, check it out!
Alteogen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alteogen and similar public comparables like Ascendis Pharma, Zhangzhou Pientzehuang, Yunnan Baiyao Group, Sobi and more.
Alteogen Overview
About Alteogen
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
Founded
2008
HQ
Employees
154
Website
Sectors
Financials (LTM)
EV
$15B
Alteogen Financials
Alteogen reported last 12-month revenue of $184M and EBITDA of $115M.
In the same LTM period, Alteogen generated $148M in gross profit, $115M in EBITDA, and $85M in net income.
Revenue (LTM)
Alteogen P&L
In the most recent fiscal year, Alteogen reported revenue of $70M and EBITDA of $27M.
Alteogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $184M | XXX | $70M | XXX | XXX | XXX |
| Gross Profit | $148M | XXX | $43M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $115M | XXX | $27M | XXX | XXX | XXX |
| EBITDA Margin | 63% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 59% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $85M | XXX | $42M | XXX | XXX | XXX |
| Net Margin | 46% | XXX | 60% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alteogen Stock Performance
Alteogen has current market cap of $15B, and enterprise value of $15B.
Market Cap Evolution
Alteogen's stock price is $277.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15B | $15B | 0.3% | XXX | XXX | XXX | $0.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlteogen Valuation Multiples
Alteogen trades at 79.0x EV/Revenue multiple, and 126.5x EV/EBITDA.
EV / Revenue (LTM)
Alteogen Financial Valuation Multiples
As of March 19, 2026, Alteogen has market cap of $15B and EV of $15B.
Equity research analysts estimate Alteogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alteogen has a P/E ratio of 173.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV/Revenue | 79.0x | XXX | 207.1x | XXX | XXX | XXX |
| EV/EBITDA | 126.5x | XXX | 539.0x | XXX | XXX | XXX |
| EV/EBIT | 132.9x | XXX | 843.6x | XXX | XXX | XXX |
| EV/Gross Profit | 98.7x | XXX | 337.7x | XXX | XXX | XXX |
| P/E | 173.8x | XXX | 350.5x | XXX | XXX | XXX |
| EV/FCF | 161.2x | XXX | 486.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alteogen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alteogen Margins & Growth Rates
Alteogen's revenue in the last 12 month grew by 116%.
Alteogen's revenue per employee in the last FY averaged $1.2M.
Alteogen's rule of 40 is 179% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alteogen's rule of X is 353% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alteogen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 116% | XXX | 101% | XXX | XXX | XXX |
| EBITDA Margin | 63% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 152% | XXX | 185% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 179% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 353% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alteogen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhangzhou Pientzehuang | XXX | XXX | XXX | XXX | XXX | XXX |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Sobi | XXX | XXX | XXX | XXX | XXX | XXX |
| Ipsen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alteogen M&A Activity
Alteogen acquired XXX companies to date.
Last acquisition by Alteogen was on XXXXXXXX, XXXXX. Alteogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alteogen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlteogen Investment Activity
Alteogen invested in XXX companies to date.
Alteogen made its latest investment on XXXXXXXX, XXXXX. Alteogen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alteogen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alteogen
| When was Alteogen founded? | Alteogen was founded in 2008. |
| Where is Alteogen headquartered? | Alteogen is headquartered in South Korea. |
| How many employees does Alteogen have? | As of today, Alteogen has over 154 employees. |
| Who is the CEO of Alteogen? | Alteogen's CEO is Soon-Jae Park. |
| Is Alteogen publicly listed? | Yes, Alteogen is a public company listed on Korea Exchange. |
| What is the stock symbol of Alteogen? | Alteogen trades under 196170 ticker. |
| When did Alteogen go public? | Alteogen went public in 2014. |
| Who are competitors of Alteogen? | Alteogen main competitors are Ascendis Pharma, Zhangzhou Pientzehuang, Yunnan Baiyao Group, Sobi. |
| What is the current market cap of Alteogen? | Alteogen's current market cap is $15B. |
| What is the current revenue of Alteogen? | Alteogen's last 12 months revenue is $184M. |
| What is the current revenue growth of Alteogen? | Alteogen revenue growth (NTM/LTM) is 116%. |
| What is the current EV/Revenue multiple of Alteogen? | Current revenue multiple of Alteogen is 79.0x. |
| Is Alteogen profitable? | Yes, Alteogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alteogen? | Alteogen's last 12 months EBITDA is $115M. |
| What is Alteogen's EBITDA margin? | Alteogen's last 12 months EBITDA margin is 63%. |
| What is the current EV/EBITDA multiple of Alteogen? | Current EBITDA multiple of Alteogen is 126.5x. |
| What is the current FCF of Alteogen? | Alteogen's last 12 months FCF is $90M. |
| What is Alteogen's FCF margin? | Alteogen's last 12 months FCF margin is 49%. |
| What is the current EV/FCF multiple of Alteogen? | Current FCF multiple of Alteogen is 161.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.